Egan JM

References (3)

Title : A phase 1, safety, tolerability, and pharmacokinetics study of bisnorcymserine, a highly selective inhibitor of butyrylcholinesterase - Tzieras_2026_Neurotherapeutics_23_e00918
Author(s) : Tzieras I , Manolopoulos A , Tweedie D , Luo W , Maccecchini M , Egan JM , Greig NH , Kapogiannis D
Ref : Neurotherapeutics , 23 :e00918 , 2026
Abstract :
PubMedSearch : Tzieras_2026_Neurotherapeutics_23_e00918
PubMedID: 42127455
Gene_locus related to this paper: human-BCHE

Title : The role of incretins in glucose homeostasis and diabetes treatment - Kim_2008_Pharmacol.Rev_60_470
Author(s) : Kim W , Egan JM
Ref : Pharmacol Rev , 60 :470 , 2008
Abstract :
PubMedSearch : Kim_2008_Pharmacol.Rev_60_470
PubMedID: 19074620

Title : Incretin-based therapies in type 2 diabetes mellitus - Chia_2008_J.Clin.Endocrinol.Metab_93_3703
Author(s) : Chia CW , Egan JM
Ref : J Clinical Endocrinology Metab , 93 :3703 , 2008
Abstract :
PubMedSearch : Chia_2008_J.Clin.Endocrinol.Metab_93_3703
PubMedID: 18628530